CClinicalTrials.gg
CompletedNCT03826004Updated Jan 13, 2020

Clemastine in Cardiovascular Surgery

An interventional study of Clemastine and Saline Solution in Efficacy and Safety, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

In this study, a prospective, randomized, double-blind pilot trial designed to evaluate the effect of histamine H1 receptor antagonist clemastine on perioperative anaphylaxis in cardiovascular surgery with cardiopulmonary bypass, especially for the efficacy and safety on reducing heparin and protamine associated anaphylaxis.

Read the detailed description

In this study, a prospective, randomized, double-blind pilot trial designed to evaluate the effect of histamine H1 receptor antagonist clemastine on perioperative anaphylaxis in cardiovascular surgery with cardiopulmonary bypass, especially for the efficacy and safety on reducing heparin and protamine associated anaphylaxis.

02

Conditions studied

  • Efficacy and Safety

Keywords

  • Cardiovascular Surgery
  • Histamine H1 Receptor Antagonist
  • Anaphylaxis
03

In context

Lead sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 141 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18-75 years old
  • Receiving selective cardiovascular surgery with cardiopulmonary bypass due to coronary, valvular or congenital heart disease
  • Written informed consent obtained.

Exclusion criteria

Exclusion Criteria:

  • Previous history of cardiac surgery
  • Allergy to clemastine, antihistamines with similar chemical structure or any excipient (sorbitol, sodium citrate, propylene glycol, ethanol)
  • Myasthenia gravis
  • Porphyria patients
  • Bronchial asthma
  • Usage of monoamine oxidase (MAO) inhibitors
  • Pregnant or lactating women
  • Mentally or legally disabled patients
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Saline solution 2ml before anesthetic induction

    Drug: Saline Solution

  • Experimental
    Clemastine

    Clemastine fumarate 2mg/2ml before anesthetic induction

    Drug: Clemastine

Interventions

  • DrugClemastine

    Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle

  • DrugSaline Solution

    Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle

06

What researchers measure

Primary outcomes

  1. Histamine concentration in plasma

    Plasma histamine concentration evaluated by ELISA

    Time frame: Perioperative period

Secondary outcomes

  1. Blood pressure

    Invasive blood pressure of radial artery: systolic, diastolic and mean pressure

    Time frame: Perioperative period

  2. Airway pressure

    Airway pressure: peak and plat

    Time frame: Perioperative period

  3. Skin manifestation

    Rate of skin manifestations, including wheal, papules, maculopapules, etc

    Time frame: Perioperative period

  4. Arrhythmia

    Rate of perioperative arrhythmia, especially tachycardia

    Time frame: Perioperative period

  5. Specific symptoms

    Rate of specific symptoms, including fatigue, sleepiness, dizziness, headache, stomach pain, constipation, nausea, dry mouth

    Time frame: Perioperative period

07

Study locations

1 site
  • Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC
    Beijing, Beijing 100037, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03826004
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Responsible party
SHI Jia (Assoticate Professor, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Feb 1, 2019
Start date
Feb 20, 2019
Primary completion
Jul 31, 2019
Completion
Jan 10, 2020
Last update
Jan 13, 2020

Study contacts

Jia Shi, M.D.
study chair · Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion